Tetra Bio-Pharma

106 articles with Tetra Bio-Pharma

• Health Canada Accepts New Drug Submission for REDUVO(TM) as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting

  6/2/2021

  Tetra Bio-Pharma Inc. announced today that Health Canada has accepted its New Drug Submission (NDS) for REDUVO™ and has formally entered the final review phase in the drug review process.

• Tetra Bio-Pharma Accelerates PLENITUDE(C) Clinical Trial to Evaluate the Effect of Cannabis for Use in Managing Uncontrolled Cancer Pain

  5/11/2021

  First ever clinical trial using pharmaceutical grade cannabis medication for use in managing uncontrolled cancer pain due to advanced cancer

• Tetra Bio-Pharma Announces Start of the REBORN1(C) Clinical Trial

  5/6/2021

  First ever Phase 2 clinical trial designed to evaluate the effect of cannabis against an opioid treatment QIXLEEF has the potential to transform the pain market

• Tetra Bio-Pharma Signs a Definitive Distribution Agreement with DanCann Pharma to Monetize Its Dronabinol and Botanical Product Portfolios

  5/5/2021

  Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development announced the signing of a Definitive Agreement with DanCann Pharma A/S for the exclusive distribution of Reduvo™ Adversa®, QIXLEEF™ and ENJOUCA™ in Denmark, Norway, Sweden, Finland, and Germany.

• Tetra Bio-Pharma Re-activates Veterinary Clinical Study in Companion Animals

  5/4/2021

  Tetra Bio-Pharma Inc. (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1) , a biopharmaceutical pioneer in immunomodulator drug discovery and development is pleased to announce that it has received authorization from the Veterinary Drugs Directorate of Health Canada for a one year extension to continue the clinical trial

• Tetra Bio-Pharma Granted a Drug Establishment License to Distribute REDUVO Soft Gel Capsules in Canada

  5/3/2021

  Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development announced that the Company has been granted a Health Canada Drug Establishment License to distribute REDUVO soft gel capsules in Canada.

• Tetra Bio-Pharma Submits Request for Scientific Advice to Malta Medicines Authority

  4/28/2021

  Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development announced that it has submitted a request to the Malta Medicines Authority for a Scientific Opinion on its investigational new drug QIXLEEF for Tetra's clinical trial programs.

• Tetra Bio-Pharma Provides an Update on its U.S. REBORN1 Clinical Trial

  4/23/2021

  Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a leader in cannabinoid-derived drug discovery and development is pleased to announce that it has shipped the investigational new drug, QIXLEEF, to the USA for the initiation of the REBORN1 study

• Tetra Bio-Pharma Announces Granting of U.S. Patent for Treatment of Interstitial Cystitis

  4/15/2021

  Tetra Bio-Pharma Inc., a biopharmaceutical pioneer in immunomodulator drug discovery and development announces the granting of a new patent from the United States Patent and Trademark Office for patent application number 16/190,450.

• Tetra Bio-Pharma Provides Update on Its New Drug Submission Application in Canada

  4/14/2021

  Tetra Bio-Pharma Inc., a biopharmaceutical pioneer in immunomodulator drug discovery and development announce they have advanced the REDUVO soft gel capsules New Drug Submission file by responding to a request for more information from Health Canada, as previously announced on March 15, 2021.

• FDA Provides Positive Feedback on Tetra Bio-Pharma's Application for ARDS-003 Clinical Development in COVID-19 Patients

  4/5/2021

  FDA acknowledged that the preclinical safety data are acceptable to file an Investigational New Drug Application (IND) aimed at treating hospitalized COVID-19 patients at risk of developing ARDS

• Tetra Bio-Pharma Receives Second Compliant Rating on Inspection from Health Canada

  4/1/2021

  Tetra Bio-Pharma Inc., a biopharmaceutical pioneer in immunomodulator drug discovery and development announce they have received a notice of compliance for its Drug Establishment License following an audit by the Drug GMP Inspection Program of Health Canada.

• Health Canada Provides Positive Feedback on Tetra Bio-Pharma’s Application for ARDS-003 to be Studied in COVID-19 Patients at Risk of Developing Acute Respiratory Distress Syndrome

  3/30/2021

  Health Canada acknowledges that the preclinical safety data are robust and sufficient to file a Clinical Trial Application aimed at treating hospitalized COVID-19 patients at risk of developing ARDS

• Tetra Bio-Pharma Initiates Additional Studies on Leading Drug Candidate ARDS-003

  3/26/2021

  Tetra Bio-Pharma and Targeted Pharmaceuticals enter into an agreement to further its collaboration and co-development activities to advance Antiviral Central Nervous System Program

• Tetra Bio-Pharma Receives Compliant Rating on Inspection from Health Canada

  3/18/2021

  Tetra Bio-Pharma Inc., a biopharmaceutical pioneer in immunomodulator drug discovery and development announce that its contract manufacturing facility, Quantum Pharma Inc., received a notice of compliance for its Drug Establishment License following an audit by the Drug GMP Inspection Program of Health Canada.

• Tetra Bio-Pharma Provides Status of Its New Drug Submission Application in Canada

  3/15/2021

  Tetra Bio-Pharma Inc., a biopharmaceutical pioneer in immunomodulator drug discovery and development announce that the Dronabinol Soft Gel capsules New Drug Submission file submitted to Health Canada on December 30, 2020 has completed the screening phase.

• Correction To Tetra Bio-Pharma News Release Dated February 25th

  3/8/2021

  Tetra Bio-Pharma Inc. (TSX: TBP) (OTCQB: TBPMF) , a biopharmaceutical pioneer in immunomodulator drug discovery and development wishes to make the following correction to its news release dated February 25th, 2021. In the statement attributed to DanCann Pharma CCO John Morell Frellsen, the estimate of peak sales by 2026 is cited at $55M DKK.

• Tetra Bio-Pharma to Present at the H.C. Wainwright Global Life Sciences Virtual Conference

  3/3/2021

  Tetra Bio-Pharma Inc. (TSX:TBP) (OTCQB:TBPMF) , a biopharmaceutical pioneer in immunomodulator drug discovery and development announces that CEO Dr. Guy Chamberland will present a company overview and hold virtual investor meetings at the H.C. Wainwright Global Life Sciences Virtual Conference being held March 9-10, 2021.

• Tetra Bio-Pharma To Monetize Its Dronabinol And Botanical Product Portfolios

  2/25/2021

  Tetra Bio-Pharma Inc. (TSX:TBP) (OTCQB:TBPMF) , a biopharmaceutical pioneer in immunomodulator drug discovery and development announced the signing of a Letter of Intent with DanCann Pharma A/S (SS: DANCAN) for the exclusive distribution of Reduvo Adversa and QIXLEEF in Denmark, Norway, Sweden, Finland, and Germany.

• Tetra Bio-Pharma Creates the ENJOUCA Business Unit

  2/3/2021

  Tetra Bio-Pharma Inc. ( TSX:TBP )( OTCQB:TBPMF ), a biopharmaceutical pioneer in immunomodulator drug discovery and development announced today the creation of a wholly-owned subsidiary called ENJOUCA;. Jurisdictions differ greatly in terms of regulatory requirements surrounding medical cannabis, which means that in some territories, QIXLEEF; can be commercialized as a medical cannabis